/VNRX
VNRX Stock - VolitionRx Limited
Healthcare|Medical - Diagnostics & ResearchAMEX
$0.26-4.26%
$0.01 (-4.26%) • Dec 19
48
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.0
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.70
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $0.28
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for VNRX
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$0.25 – $0.26
TARGET (TP)$0.29
STOP LOSS$0.24
RISK/REWARD1:2.1
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.26
52W High$0.94
52W Low$0.23
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $1.23M | $775,302 | $306,392 | $90,035 | $13,433 |
| Gross Profit | $1.23M | $775,302 | $306,392 | $90,035 | $13,433 |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating Income | $-27,024,970 | $-35,987,695 | $-31,780,072 | $-28,333,079 | $-21,247,815 |
| Net Income | $-26,967,836 | $-35,319,078 | $-30,268,793 | $-26,814,665 | $-20,352,115 |
| Net Margin | -2186.3% | -4555.5% | -9879.1% | -29782.5% | -151508.3% |
| EPS | $-0.31 | $-0.50 | $-0.55 | $-0.51 | $-0.45 |
Company Overview
VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose a range of cancers and other diseases worldwide. It sells Nu.Q that detect cancer; Nu.Q Nets, monitoring the immune system; Nu.Q Vet cancer screening test for veterinary applications; Nu.Q Capture capturing and concentrating samples for more accurate diagnosis; and Nu.Q Discover, a solution to profiling nucleosomes. The company operates Nucleosomics a technology platform for blood test. VolitionRx Limited is based in Austin, Texas.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
1
50%
Hold / Neutral
1
50%
Sell / Underperform
0%
Analyst Consensus🟡 Mixed
1 Bullish1 Neutral/Bearish
Price Targets
$3
Average Target
↑ 876.6% Upside
Now
$3
Low
$3
Average
$3
High
Based on 1 analyst
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| April 8th 2025 | H.C. Wainwright | Initiation | Buy | $2.5 |
| February 1st 2023 | The Benchmark Company | Downgrade | Hold | - |
Earnings History & Surprises
VNRXBeat Rate
37%
Last 19 quarters
Avg Surprise
-47.4%
EPS vs Estimate
Beats / Misses
7/6
6 met exactly
Latest EPS
$-0.04
Q4 2025
EPS Surprise History
Q1 24
0.0%
$-0.11vs$-0.11
Q2 24
+9.1%
$-0.10vs$-0.11
Q3 24
+11.1%
$-0.08vs$-0.09
Q4 24
0.0%
$-0.07vs$-0.07
Q1 25
0.0%
$-0.06vs$-0.06
Q2 25
0.0%
$-0.06vs$-0.06
Q3 25
-20.0%
$-0.06vs$-0.05
Q4 25
0.0%
$-0.04vs$-0.04
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 30, 2026 | $-0.02 | — | — | — |
Q4 2025 | Nov 13, 2025 | $-0.04 | $-0.04 | 0.0% | = MET |
Q3 2025 | Aug 14, 2025 | $-0.05 | $-0.06 | -20.0% | ✗ MISS |
Q2 2025 | May 15, 2025 | $-0.06 | $-0.06 | 0.0% | = MET |
Q1 2025 | Mar 31, 2025 | $-0.06 | $-0.06 | 0.0% | = MET |
Q4 2024 | Nov 14, 2024 | $-0.07 | $-0.07 | 0.0% | = MET |
Q3 2024 | Aug 14, 2024 | $-0.09 | $-0.08 | +11.1% | ✓ BEAT |
Q2 2024 | May 13, 2024 | $-0.11 | $-0.10 | +9.1% | ✓ BEAT |
Q1 2024 | Mar 25, 2024 | $-0.11 | $-0.11 | 0.0% | = MET |
Q4 2023 | Nov 14, 2023 | $-0.12 | $-0.11 | +8.3% | ✓ BEAT |
Q3 2023 | Aug 14, 2023 | $-0.13 | $-0.14 | -7.7% | ✗ MISS |
Q2 2023 | May 10, 2023 | $-0.14 | $-0.15 | -7.1% | ✗ MISS |
Q1 2023 | Mar 15, 2023 | $-0.15 | $-0.13 | +13.3% | ✓ BEAT |
Q4 2022 | Nov 14, 2022 | $-0.15 | $-0.14 | +6.7% | ✓ BEAT |
Q3 2022 | Aug 10, 2022 | $-0.15 | $-0.14 | +6.7% | ✓ BEAT |
Q2 2022 | May 11, 2022 | $-0.01 | $-0.14 | -900.0% | ✗ MISS |
Q1 2022 | Mar 30, 2022 | $-0.14 | $-0.15 | -7.1% | ✗ MISS |
Q4 2021 | Nov 10, 2021 | $-0.10 | $-0.13 | -30.0% | ✗ MISS |
Q3 2021 | Aug 11, 2021 | $-0.12 | $-0.10 | +16.7% | ✓ BEAT |
Q2 2021 | May 11, 2021 | $-0.12 | $-0.12 | 0.0% | = MET |
Latest News
VolitionRX shares are trading lower after D. Boral Capital lowered the price target from $5 to $3.
📉 NegativeBenzinga•Dec 18, 2025, 05:33 PM
D. Boral Capital Maintains Buy on VolitionRX, Lowers Price Target to $3
➖ NeutralBenzinga•Dec 18, 2025, 12:23 PM
VolitionRx shares are trading higher after the company issued a business review of 2025.
📈 PositiveBenzinga•Dec 17, 2025, 08:50 PM
VolitionRx Issues 2025 Business Review
➖ NeutralBenzinga•Dec 17, 2025, 01:46 PM
VolitionRx Presents Two Abstracts At NACLC In Chicago Highlighting Use Of Its Nu.Q Cancer Assays In Management Of Lung Cancer Patients
📈 PositiveBenzinga•Dec 8, 2025, 02:07 PM
D. Boral Capital Maintains Buy on VolitionRX, Maintains $5 Price Target
📈 PositiveBenzinga•Dec 4, 2025, 06:05 PM
VolitionRx Announces Inclusion Of Its Nu.Q NETs H3.1 Assay In DETECSEPS Consortium
📈 PositiveBenzinga•Dec 4, 2025, 02:06 PM
Maxim Group Downgrades VolitionRX to Hold
📉 NegativeBenzinga•Dec 3, 2025, 07:09 PM
D. Boral Capital Maintains Buy on VolitionRX, Maintains $5 Price Target
📈 PositiveBenzinga•Nov 26, 2025, 05:56 PM
VNRX stock has given up its prior gain. VolitionRx shares were trading higher after the company announced the first sale of its Nu.Q Cancer assays to Hospices Civils de Lyon.
➖ NeutralBenzinga•Nov 25, 2025, 02:56 PM
VolitionRx shares are trading higher after the company announced the first sale of its Nu.Q Cancer assays to Hospices Civils de Lyon.
📈 PositiveBenzinga•Nov 25, 2025, 01:49 PM
VolitionRx Announces The First Sale Of The Nu.Q Cancer Assays For Clinical Certification In Preparation For Routine Clinical Use To One Of Europe's Leading Cancer Centers, The Hospices Civils De Lyon, In Lyon, France
📈 PositiveBenzinga•Nov 25, 2025, 01:47 PM
HC Wainwright & Co. Maintains Buy on VolitionRX, Lowers Price Target to $1.5
➖ NeutralBenzinga•Nov 17, 2025, 04:30 PM
D. Boral Capital Maintains Buy on VolitionRX, Maintains $5 Price Target
📈 PositiveBenzinga•Nov 17, 2025, 01:10 PM
VolitionRX Q3 EPS $(0.05) Misses $(0.04) Estimate, Sales $627.277K Miss $1.681M Estimate
📉 NegativeBenzinga•Nov 13, 2025, 09:25 PM
VolitionRX shares are trading lower after the company announced pricing of $6 million offering of common stock and warrants.
📉 NegativeBenzinga•Oct 10, 2025, 03:14 PM
VolitionRx Limited Announces Pricing Of Underwritten Public Offering Of 11.55M Shares Of Common Stock And Accompanying Warrants At $0.52 Per Unit
📉 NegativeBenzinga•Oct 10, 2025, 12:35 PM
VolitionRX shares are trading lower after the company announced a public offering.
📉 NegativeBenzinga•Oct 9, 2025, 08:09 PM
VolitionRx Announces Proposed Underwritten Public Offering Of Common Stock And Common Stock Warrants; No Terms Disclosed
➖ NeutralBenzinga•Oct 9, 2025, 08:07 PM
D. Boral Capital Maintains Buy on VolitionRX, Maintains $5 Price Target
📈 PositiveBenzinga•Sep 29, 2025, 04:37 PM
Frequently Asked Questions about VNRX
What is VNRX's current stock price?
VolitionRx Limited (VNRX) is currently trading at $0.26 per share. The stock has moved -4.26% today.
What is the analyst price target for VNRX?
No analyst price targets are currently available for this stock.
What sector is VolitionRx Limited in?
VolitionRx Limited operates in the Healthcare sector, specifically within the Medical - Diagnostics & Research industry. The company is traded on the AMEX exchange.
What is VNRX's market cap?
VolitionRx Limited has a market capitalization of $0.03 billion, making it a small-cap company.
Does VNRX pay dividends?
No, VolitionRx Limited does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorALGS
Aligos Therapeutics, Inc.
$10.68
Mkt Cap: $0.1B
BDSX
Biodesix, Inc.
$6.69
Mkt Cap: $0.0B
CTSO
Cytosorbents Corporation
$0.64
Mkt Cap: $0.0B
INMB
INmune Bio, Inc.
$1.83
Mkt Cap: $0.0B
MDCX
Medicus Pharma Ltd. Common Stock
$1.69
Mkt Cap: $0.0B
MRSN
Mersana Therapeutics, Inc.
$28.94
Mkt Cap: $0.1B
NOTV
Inotiv, Inc.
$0.67
Mkt Cap: $0.0B
SKYE
Skye Bioscience, Inc.
$0.93
Mkt Cap: $0.0B
WGRX
Wellgistics Health, Inc.
$0.49
Mkt Cap: $0.0B
XLO
Xilio Therapeutics, Inc.
$0.67
Mkt Cap: $0.0B
Explore stocks similar to VNRX for comparison